Patent Assignment
Reel/Frame 012374/0696
Assignment of Assignor's Interest
Recorded: 2001-12-18
Pages: 6
Assignors
KURTHY, MARIA
Executed: 2001-09-18
BIRO, KATALIN
Executed: 2001-09-19
NAGY, KAROLY
Executed: 2001-11-10
UROGDI, LASZLO
Executed: 2001-09-18
CSAKAI, ZITA
Executed: 2001-09-18
SZILBEREKY, JENO
Executed: 2001-09-19
MOGYOROSI, TAMAS
Executed: 2001-09-18
TOROK, MAGDOLNA
Executed: 2001-09-18
KOMAROMI, ANDRAS
Executed: 2001-09-29
MARVANYOS, EDE
Executed: 2001-09-18
BARABAS, MIHALY
Executed: 2001-09-18
KARDOS, MIHALYNE
Executed: 2001-09-18
NAGY, ZOLTAN
Executed: 2001-11-09
KORANYI, LASZLO
Executed: 2001-11-10
NAGY, MELINDA
Executed: 2001-09-18
Assignee
BIOREX KUTATO ES FEJLESZTO RT.
PF. 348 H-8201 VESZPREM-SZABADSAGPUSZTA, HUNGARY
Covered Property
(1)
N-[2-Hydroxy-3-(1-Piperidinyl)Propoxy}Pyridine-1-Oxide-3-Carboximidoyl Chlorine and Its Use in the Treatment of Unsulin Resistance
Patent:
6,649,628 →
Application:
09/913,263 →
Related Assignments
(9)
Other recorded transfers of the patent in this record — the chain of ownership.
Assignment of Assignor's Interest
Jul 15, 2005
From: BIROREX KUTATO ES FEJLESZTO RT.
To: CYTRX CORPORATION
Reel/Frame 016784/0135 →
Assignment of Assignor's Interest
Aug 29, 2005
From: BIOREX KUTATÓ ÉS FEJLESZTÖ RT. ("V.A."); BRX RESEARCH AND DEVELOPMENT COMPANY LTD
To: CYTRX CORPORATION
Reel/Frame 016460/0725 →
Assignment of Assignor's Interest
Dec 6, 2006
From: BRX MAGYARORSZAG RT
To: CYTRX CORPORATION
Reel/Frame 018590/0620 →
Assignment of Assignor's Interest
Mar 21, 2012
From: CYTRX CORPORATION
To: ORPHAZYME APS
Reel/Frame 027901/0269 →
Change of Name
Apr 11, 2018
From: ORPHAZYME APS
To: ORPHAZYME A/S
Reel/Frame 045911/0992 →
Security Interest
Sep 6, 2019
From: ORPHAZYME A/S; ORPHAZYME US, INC.
To: KREOS CAPITAL VI (UK) LIMITED
Reel/Frame 050294/0026 →
Assignment of Assignor's Interest
Jul 6, 2022
From: KEMPHARM, INC.
To: KEMPHARM DENMARK A/S
Reel/Frame 060592/0595 →
Assignment of Assignor's Interest
Jul 6, 2022
From: ORPHAZYME A/S
To: KEMPHARM, INC.
Reel/Frame 060592/0646 →
Release of Security Interest
Apr 4, 2024
From: KREOS CAPITAL VI (UK) LIMITED
To: ZEVRA DENMARK A/S (F/K/A KEMPHARM DENMARK A/S, SUCCESSOR IN INTEREST TO ORPHAZYME A/S)
Reel/Frame 067007/0706 →